Dr. Martin Spahn presented “Next Generation Sequencing of Prostate Tumors: Use of Individualized Biomarkers for Prognosis and Treatment” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: prostate cancer, biomarkers, gene mutations, next generation sequencing
How to cite: Spahn, Martin. “Next Generation Sequencing of Prostate Tumors: Use of Individualized Biomarkers for Prognosis and Treatment” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2024. https://dev.grandroundsinurology.com/next-generation-sequencing-prostate-tumors
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Dr. Martin Spahn is a Senior Consultant in the Department of Urology at the Lindenhofspital Bern in Bern, Switzerland. His professional career began in Germany: he graduated in Medicine in 1993 and specialized in Urology and Surgical Urology at the University of Mannheim. In 2007, he was appointed Adjunct Clinical Head at the Department of Urology of the Community Hospital in Karlsruhe, Germany. He then held a position in the Department of Urology and Pediatric Urology at the University Hospital in Würzburg, Germany, where he worked until 2012 before moving to the Inselspital Bern, where he was a Senior Consultant in the Department of Urology until 2018. Dr. Spahn is a member of several scientific societies, including the AUA and the EAU. Dr. Spahn has published over 70 papers in peer-reviewed journals. He is a reviewer for several journals, including European Urology, the British Medical Journal, and the Journal of Urology. He also serves as a grant reviewer for several scientific organisations in Europe, including Cancer Research UK, the German Cancer League, and the Swiss National Fund. He received several awards for his translational research in high-risk prostate cancer, including the Prostate Cancer Research Award of the EAU in 2015 and the Urological Oncology Award of the EAU in 2011.
